Exciting News from Pharvaris
Pharvaris (NASDAQ: PHVS), a late-stage biopharmaceutical company situated in Switzerland, has made significant strides in developing innovative, oral bradykinin B2 receptor antagonists. Their mission focuses on addressing critical needs for individuals suffering from diseases related to bradykinin, notably hereditary angioedema (HAE) and acquired angioedema associated with C1 inhibitor deficiency.
Upcoming Congress Presentations
This year, Pharvaris proudly announces the acceptance of abstracts for presentation at three crucial congresses, where the company will showcase cutting-edge data from its clinical studies. The congresses include the renowned C1-Inhibitor Deficiency and Angioedema Workshop, held in Budapest, along with the Eastern Allergy Conference in Palm Beach and the EAACI Congress in Glasgow.
C1-Inhibitor Deficiency and Angioedema Workshop
The C1-Inhibitor Deficiency and Angioedema Workshop, scheduled for the end of May, will serve as a platform for several key presentations. These include:
- Clinical Validation of a Novel Biomarker Assay: This oral presentation by Evangelia Pardali, Ph.D., will discuss a groundbreaking biomarker assay aimed at characterizing bradykinin-mediated angioedema using plasma samples.
- Long-Term Prophylactic Treatment with Deucrictibant: Presented by Markus Magerl, M.D., this session will highlight how long-term treatment with Deucrictibant can enhance health-related quality of life for patients with HAE.
- Results of Pharmacokinetics Study: Zhi-Yi Zhang, Ph.D. will present findings from a study assessing the sustained therapeutic exposure from once-daily Deucrictibant XR tablets.
- Patient Experience in Acquired Angioedema: Andrea Zanichelli, M.D., Ph.D. will address patient-reported outcomes in individuals with acquired angioedema.
- Trial Results from CHAPTER-1: Emel Aygören-Pürsün, M.D. will discuss the long-term safety and efficacy of Deucrictibant from the CHAPTER-1 study.
Eastern Allergy Conference Highlights
At the Eastern Allergy Conference, two notable presentations by John Anderson, M.D. will provide insights into:
- Long-term safety and efficacy of Deucrictibant for prophylaxis against HAE.
- The treatment of hereditary angioedema attacks, presenting significant results from the RAPIDe-2 Extension Study.
EAACI Congress Contributions
The EAACI Congress scheduled for June will feature impactful presentations, including a flash talk from Evangelia Pardali, Ph.D. on the clinical validation of a novel kinin biomarker assay. Additionally, Emel Aygören-Pürsün, M.D. will delve into the long-term efficacy of Deucrictibant during thematic sessions.
Emphasizing Quality of Life
Pharvaris emphasizes the importance of improving the quality of life for individuals with bradykinin-mediated angioedema. The upcoming presentations will demonstrate how their innovative therapies hold the promise not only for efficacy but also for enhanced tolerability.
Company Goals and Future Directions
Pharvaris is committed to providing injectable-like efficacy coupled with the convenience of oral treatment options. They are currently evaluating their flagship product, Deucrictibant, in pivotal Phase 3 studies aimed at preventing and treating HAE attacks, underscoring their dedication to addressing unmet medical needs.
Frequently Asked Questions
What is the focus of Pharvaris?
Pharvaris specializes in developing oral bradykinin B2 receptor antagonists to treat bradykinin-mediated diseases, specifically hereditary and acquired angioedema.
When will the congress presentations occur?
The presentations are scheduled for events taking place at the end of May and mid-June, including the C1-Inhibitor Workshop, Eastern Allergy Conference, and EAACI Congress.
Who is presenting the clinical data?
Several esteemed researchers and doctors will be presenting, including Evangelia Pardali, Ph.D., and Markus Magerl, M.D., among others.
What is the main goal of these presentations?
The goal is to share groundbreaking clinical data and biomarker studies, demonstrating the safety and efficacy of Deucrictibant while improving patient outcomes.
Where can I find more information about Pharvaris?
For more details about the company, its research, and its clinical developments, you can visit the Pharvaris website.
